Immunology, signal transduction, and behavior in hypothalamic-pituitary- adrenal axis-related genetic mouse models

Annals of the New York Academy of Sciences

Volumn 1153, Issue , 2009, Pages 120-130

  Silberstein, Susana ^a   Vogl, Annette M ^b   Bonfiglio, Juán José ^a   Wurst, Wolfgang ^b,c   Holsboer, Florian ^b   Arzt, Eduardo ^a,d   Deussing, Jan M ^b   Refojo, Damián ^a,b  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d INSTITUTO DE FISIOLOGÍA   (Argentina)

Author keywords

Behavior; CRF; CRH; ERK; Forced swim test; HPA axis; MAPK; Mouse models; Stress; Stress coping behavior; endorphin

Indexed keywords

BETA ENDORPHIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CYTOKINE; MITOGEN ACTIVATED PROTEIN KINASE;

CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; COPING BEHAVIOR; CYTOKINE PRODUCTION; GENE OVEREXPRESSION; GENETIC ENGINEERING; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; NEUROENDOCRINE SYSTEM; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 60349091742     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2008.03967.x     Document Type: Conference Paper

References (73)

1. Smith, S.M. & W.W. Vale. 2006. The role of the hypothalamic- pituitary-adrenal axis in neuroendocrine responses to stress. Dialogues Clin. Neurosci. 8 : 383 395.
2. de Kloet, E.R., M. Joels & F. Holsboer. 2005. Stress and the brain: from adaptation to disease. Nat. Rev. Neurosci. 6 : 463 475.
3. Hillhouse, E.W. & D.K. Grammatopoulos. 2006. The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology. Endocr. Rev. 27 : 260 286.
4. Besedovsky, H.O. & R.A. del Rey. 1996. Immune-neuro-endocrine interactions: facts and hypotheses. Endocr. Rev. 17 : 64 102.
5. Branda, C.S. & S.M. Dymecki. 2004. Talking about a revolution: the impact of site-specific recombinases on genetic analyses in mice. Dev. Cell 6 : 7 28.
6. Deussing, J.M. & W. Wurst. 2005. Dissecting the genetic effect of the CRH system on anxiety and stress-related behaviour. C.R. Biol. 328 : 199 212.
7. Bale, T.L. & W.W. Vale. 2004. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu. Rev. Pharmacol. Toxicol. 44 : 525 557.
8. Herman, J.P., H. Figueiredo, N.K. Mueller, et al. 2003. Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo-pituitary-adrenocortical responsiveness. Front Neuroendocrinol. 24 : 151 180.
9. Korosi, A. & T.Z. Baram. 2008. The central corticotropin releasing factor system during development and adulthood. Eur. J. Pharmacol. 583 : 204 214.
10. Smagin, G.N., S.C. Heinrichs & A.J. Dunn. 2001. The role of CRH in behavioral responses to stress. Peptides 22 : 713 724.
11. Arborelius, L., M.J. Owens, P.M. Plotsky, et al. 1999. The role of corticotropin-releasing factor in depression and anxiety disorders. J. Endocrinol. 160 : 1 12.
12. Buzzetti, R., L. McLoughlin, P.M. Lavender, et al. 1989. Expression of pro-opiomelanocortin gene and quantification of adrenocorticotropic hormone-like immunoreactivity in human normal peripheral mononuclear cells and lymphoid and myeloid malignancies. J. Clin. Invest. 83 : 733 737.
13. Lyons, P.D. & J.E. Blalock. 1997. Pro-opiomelanocortin gene expression and protein processing in rat mononuclear leukocytes. J. Neuroimmunol. 78 : 47 56.
14. Cabot, P.J., L. Carter, C. Gaiddon, et al. 1997. Immune cell-derived beta-endorphin. Production, release, and control of inflammatory pain in rats. J. Clin. Invest. 100 : 142 148.
15. Smith, E.M. & J.E. Blalock. 1981. Human lymphocyte production of corticotropin and endorphin-like substances: association with leukocyte interferon. Proc. Natl. Acad. Sci. USA 78 : 7530 7534.
16. Kavelaars, A., R.E. Ballieux & C.J. Heijnen. 1989. The role of IL-1 in the corticotropin-releasing factor and arginine-vasopressin-induced secretion of immunoreactive beta-endorphin by human peripheral blood mononuclear cells. J. Immunol. 142 : 2338 2342.
17. Blalock, J.E. 1998. Beta-endorphin in immune cells. Immunol. Today 19 : 191 192.
18. Panerai, A.E. & P. Sacerdote. 1997. Beta-endorphin in the immune system: a role at last? Immunol. Today 18 : 317 319.
19. Apte, R.N., S.K. Durum & J.J. Oppenheim. 1990. Opioids modulate interleukin-1 production and secretion by bone-marrow macrophages. Immunol. Lett. 24 : 141 148.
20. Hosoi, J., H. Ozawa & R.D. Granstein. 1999. beta-Endorphin binding and regulation of cytokine expression in Langerhans cells. Ann. N. Y. Acad. Sci. 885 : 405 413.
21. Kovalovsky, D., M.P. Pereda, G.K. Stalla, et al. 1999. Differential regulation of interleukin-1 receptor antagonist by proopiomelanocortin peptides adrenocorticotropic hormone and beta-endorphin. Neuroimmunomodulation 6 : 367 372.
22. Belkowski, S.M., C. Alicea, T.K. Eisenstein, et al. 1995. Inhibition of interleukin-1 and tumor necrosis factor-alpha synthesis following treatment of macrophages with the kappa opioid agonist U50, 488H. J. Pharmacol. Exp. Ther. 273 : 1491 1496.
23. Chao, C.C., T.W. Molitor, K. Close, et al. 1993. Morphine inhibits the release of tumor necrosis factor in human peripheral blood mononuclear cell cultures. Int. J. Immunopharmacol. 15 : 447 453.
24. Fontana, L., A. Fattorossi, R. D'Amelio, et al. 1987. Modulation of human concanavalin A-induced lymphocyte proliferative response by physiological concentrations of beta-endorphin. Immunopharmacology 13 : 111 115.
25. Gilmore, W. & L.P. Weiner. 1989. The opioid specificity of beta-endorphin enhancement of murine lymphocyte proliferation. Immunopharmacology 17 : 19 30.
26. Van den Bergh, P., J. Rozing & L. Nagelkerken. 1991. Two opposing modes of action of beta-endorphin on lymphocyte function. Immunology 72 : 537 543.
27. Puppo, F., G. Corsini, P. Mangini, et al. 1985. Influence of beta-endorphin on phytohemagglutinin-induced lymphocyte proliferation and on the expression of mononuclear cell surface antigens in vitro. Immunopharmacology 10 : 119 125.
28. Panerai, A.E., B. Manfredi, F. Granucci, et al. 1995. The beta-endorphin inhibition of mitogen-induced splenocytes proliferation is mediated by central and peripheral paracrine/autocrine effects of the opioid. J. Neuroimmunol. 58 : 71 76.
29. Rubinstein, M., J.S. Mogil, M. Japon, et al. 1996. Absence of opioid stress-induced analgesia in mice lacking beta-endorphin by site-directed mutagenesis. Proc. Natl. Acad. Sci. USA 93 : 3995 4000.
30. Refojo, D., D. Kovalovsky, J.I. Young, et al. 2002. Increased splenocyte proliferative response and cytokine production in beta-endorphin-deficient mice. J. Neuroimmunol. 131 : 126 134.
31. Swanson, L.W., P.E. Sawchenko, J. Rivier, et al. 1983. Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology 36 : 165 186.
32. Grigoriadis, D.E. 2005. The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders. Expert. Opin. Ther. Targets 9 : 651 684.
33. Holsboer, F. & M. Ising. 2008. Central CRH system in depression and anxiety - evidence from clinical studies with CRH1 receptor antagonists. Eur. J. Pharmacol. 583 : 350 357.
34. Todorovic, C., O. Jahn, H. Tezval, et al. 2005. The role of CRF receptors in anxiety and depression: implications of the novel CRF1 agonist cortagine. Neurosci. Biobehav. Rev. 29 : 1323 1333.
35. Bittencourt, J.C. & P.E. Sawchenko. 2000. Do centrally administered neuropeptides access cognate receptors?: an analysis in the central corticotropin-releasing factor system. J. Neurosci. 20 : 1142 1156.
36. Van Pett, K, V. Viau, J.C. Bittencourt, et al. 2000. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J. Comp Neurol. 428 : 191 212.
37. Hauger, R.L., V. Risbrough, O. Brauns, et al. 2006. Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol. Disord. Drug Targets 5 : 453 479.
38. Timpl, P., R. Spanagel, I. Sillaber, et al. 1998. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin- releasing hormone receptor 1. Nat. Genet. 19 : 162 166.
39. Smith, G.W., J.M. Aubry, F. Dellu, et al. 1998. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20 : 1093 1102.
40. Arzt, E. & F. Holsboer. 2006. CRF signaling: molecular specificity for drug targeting in the CNS. Trends Pharmacol. Sci. 27 : 531 538.
41. Philips, A., S. Lesage, R. Gingras, et al. 1997. Novel dimeric Nur77 signaling mechanism in endocrine and lymphoid cells. Mol. Cell Biol. 17 : 5946 5951.
42. Kovalovsky, D., D. Refojo, A.C. Liberman, et al. 2002. Activation and induction of NUR77/NURR1 in corticotrophs by CRH/cAMP: involvement of calcium, protein kinase A, and MAPK pathways. Mol. Endocrinol. 16 : 1638 1651.
43. Brar, B.K., A. Chen, M.H. Perrin, et al. 2004. Specificity and regulation of extracellularly regulated kinase1/2 phosphorylation through corticotropin-releasing factor (CRF) receptors 1 and 2beta by the CRF/urocortin family of peptides. Endocrinology 145 : 1718 1729.
44. Grammatopoulos, D.K., H.S. Randeva, M.A. Levine, et al. 2000. Urocortin, but not corticotropin-releasing hormone (CRH), activates the mitogen-activated protein kinase signal transduction pathway in human pregnant myometrium: an effect mediated via R1alpha and R2beta CRH receptor subtypes and stimulation of Gq-proteins. Mol. Endocrinol. 14 : 2076 2091.
45. Bayatti, N., J. Zschocke & C. Behl. 2003. Brain region-specific neuroprotective action and signaling of corticotropin-releasing hormone in primary neurons. Endocrinology 144 : 4051 4060.
46. Elliott-Hunt, C.R., J. Kazlauskaite, G.J. Wilde, et al. 2002. Potential signalling pathways underlying corticotrophin-releasing hormone-mediated neuroprotection from excitotoxicity in rat hippocampus. J. Neurochem. 80 : 416 425.
47. Swinny, J.D., F. Metzger, J. IJkema-Paassen, et al. 2004. Corticotropin-releasing factor and urocortin differentially modulate rat Purkinje cell dendritic outgrowth and differentiation in vitro. Eur. J. Neurosci. 19 : 1749 1758.
48. Di Benedetto B., C. Hitz, S.M. Holter, et al. 2007. Differential mRNA distribution of components of the ERK/MAPK signalling cascade in the adult mouse brain. J. Comp Neurol. 500 : 542 556.
49. Ailing, F., L. Fan, S. Li, et al. 2008. Role of extracellular signal-regulated kinase signal transduction pathway in anxiety. J. Psychiatr. Res. 43 : 55 63.
50. Meller, E., C. Shen, T.A. Nikolao, et al. 2003. Region-specific effects of acute and repeated restraint stress on the phosphorylation of mitogen-activated protein kinases. Brain Res. 979 : 57 64.
51. Einat, H., P. Yuan, T.D. Gould, et al. 2003. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J. Neurosci. 23 : 7311 7316.
52. Duman, C.H., L. Schlesinger, M. Kodama, et al. 2007. A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment. Biol. Psychiatry 61 : 661 670.
53. Tronson, N.C., C. Schrick, A. Fischer, et al. 2008. Regulatory mechanisms of fear extinction and depression-like behavior. Neuropsychopharmacology 33 : 1570 1583.
54. Refojo, D., C. Echenique, M.B. Muller, et al. 2005. Corticotropin- releasing hormone activates ERK1/2 MAPK in specific brain areas. Proc. Natl. Acad. Sci. USA 102 : 6183 6188.
55. Muller, M.B., S. Zimmermann, I. Sillaber, et al. 2003. Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat. Neurosci. 6 : 1100 1107.
56. Qi, X., W. Lin, J. Li, et al. 2006. The depressive-like behaviors are correlated with decreased phosphorylation of mitogen-activated protein kinases in rat brain following chronic forced swim stress. Behav. Brain Res. 175 : 233 240.
57. Dwivedi, Y., H.S. Rizavi, R.C. Roberts, et al. 2001. Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. J. Neurochem. 77 : 916 928.
58. Di Benedetto B., M. Kallnik, D.M. Weisenhorn, et al. 2008. Activation of ERK/MAPK in the Lateral Amygdala of the Mouse is Required for Acquisition of a Fear-Potentiated Startle response. Neuropsychopharmacology In press.
59. Fischer, A., M. Radulovic, C. Schrick, et al. 2007. Hippocampal Mek/Erk signaling mediates extinction of contextual freezing behavior. Neurobiol. Learn. Mem. 87 : 149 158.
60. Berton, O. & E.J. Nestler. 2006. New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev. Neurosci. 7 : 137 151.
61. Nemeroff, C.B., E. Widerlov, G. Bissette, et al. 1984. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 226 : 1342 1344.
62. Holsboer, F., U. von Bardeleben, A. Gerken, et al. 1984. Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. N. Engl. J. Med. 311 : 1127.
63. Raadsheer, F.C., W.J. Hoogendijk, F.C. Stam, et al. 1994. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 60 : 436 444.
64. Nemeroff, C.B., M.J. Owens, G. Bissette, et al. 1988. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch. Gen. Psychiatry 45 : 577 579.
65. Dunn, A.J. & C.W. Berridge. 1990. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res. Brain Res. Rev. 15 : 71 100.
66. Tamminga, C.A., C.B. Nemeroff, R.D. Blakely, et al. 2002. Developing novel treatments for mood disorders: accelerating discovery. Biol. Psychiatry 52 : 589 609.
67. Stenzel-Poore, M.P., V.A. Cameron, J. Vaughan, et al. 1992. Development of Cushing's syndrome in corticotropin-releasing factor transgenic mice. Endocrinology 130 : 3378 3386.
68. Groenink, L., T. Pattij, J.R. De, et al. 2003. 5-HT1A receptor knockout mice and mice overexpressing corticotropin-releasing hormone in models of anxiety. Eur. J. Pharmacol. 463 : 185 197.
69. Tronche, F., C. Kellendonk, O. Kretz, et al. 1999. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat. Genet. 23 : 99 103.
70. Lu, A., M.A. Steiner, N. Whittle, et al. 2008. Conditional mouse mutants highlight mechanisms of corticotropin-releasing hormone effects on stress-coping behavior. Mol. Psychiatry 13 : 1028 1042.
71. Hasler, G., W.C. Drevets, H.K. Manji, et al. 2004. Discovering endophenotypes for major depression. Neuropsychopharmacology 29 : 1765 1781.
72. van Gaalen, M.M., J.H. Reul, A. Gesing, et al. 2002. Mice overexpressing CRH show reduced responsiveness in plasma corticosterone after a5-HT1A receptor challenge. Genes Brain Behav. 1 : 174 177.
73. Steckler, T. & F. Holsboer. 1999. Corticotropin-releasing hormone receptor subtypes and emotion. Biol. Psychiatry 46 : 1480 1508.